Harrow, Inc. (NASDAQ:HROW) Shares Purchased by D. E. Shaw & Co. Inc.

D. E. Shaw & Co. Inc. increased its holdings in Harrow, Inc. (NASDAQ:HROW - Free Report) by 6.7% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 664,714 shares of the company's stock after buying an additional 41,896 shares during the period. D. E. Shaw & Co. Inc. owned about 1.87% of Harrow worth $22,301,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Vanguard Group Inc. boosted its position in shares of Harrow by 0.3% in the 4th quarter. Vanguard Group Inc. now owns 1,872,100 shares of the company's stock worth $62,809,000 after buying an additional 5,225 shares in the last quarter. Braidwell LP boosted its position in shares of Harrow by 106.3% in the 4th quarter. Braidwell LP now owns 907,039 shares of the company's stock worth $30,431,000 after buying an additional 467,401 shares in the last quarter. Northern Trust Corp boosted its position in shares of Harrow by 7.5% in the 4th quarter. Northern Trust Corp now owns 319,084 shares of the company's stock worth $10,705,000 after buying an additional 22,266 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Harrow by 1.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 255,218 shares of the company's stock worth $8,563,000 after buying an additional 3,589 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its position in shares of Harrow by 443.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 238,367 shares of the company's stock worth $10,717,000 after buying an additional 194,480 shares in the last quarter. 72.76% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently commented on HROW. HC Wainwright boosted their price objective on shares of Harrow from $57.00 to $60.00 and gave the stock a "buy" rating in a research report on Monday. B. Riley reduced their target price on shares of Harrow from $69.00 to $65.00 and set a "buy" rating on the stock in a report on Tuesday, April 1st.

Harrow Trading Down 4.3%

NASDAQ:HROW traded down $1.14 on Wednesday, reaching $25.13. The stock had a trading volume of 512,290 shares, compared to its average volume of 500,321. The company has a market cap of $921.89 million, a price-to-earnings ratio of -26.73 and a beta of 0.41. The company has a debt-to-equity ratio of 3.23, a current ratio of 1.55 and a quick ratio of 1.44. The firm's fifty day moving average is $24.85 and its two-hundred day moving average is $32.27. Harrow, Inc. has a 12-month low of $15.78 and a 12-month high of $59.23.

Harrow (NASDAQ:HROW - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.02 by ($0.40). The firm had revenue of $47.83 million during the quarter, compared to analysts' expectations of $57.00 million. Harrow had a negative net margin of 19.75% and a negative return on equity of 45.57%. Equities analysts expect that Harrow, Inc. will post -0.53 EPS for the current fiscal year.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.